It's earnings season—a time when publicly traded pharmas and biotechs tell their investors how they've performed over the previous quarter. But aside from drug sales figures, it’s a great opportunity to get a sense of how these companies' pipelines have changed. We'll dig into that, and even the stuff that companies are less keen to talk about. 

Regeneron once boasted one of the top COVID-19 therapeutics in its antibody cocktail REGEN-COV. Now, the company is terminating four studies for the med across a range of patients and clinical stages. The move follows the FDA’s decision to pull the medication from the market in January, citing uncertain efficacy against the surging omicron variant. And Regeneron’s antibody combo isn’t alone. We'll discuss how early pandemic therapeutics have fallen by the wayside.

To learn more about the topics in this episode: 
AstraZeneca axes Moderna-partnered, phase 2 heart disease drug plus a Wee inhibitor
BMS-Ambrx collab runs out of steam after FA relaxin med canned
Takeda cuts ties to cancer drug landed in $120M Turnstone deal
The NASH curse strikes again. Pfizer dumps early-stage asset for liver condition
AstraZeneca axes Moderna-partnered, phase 2 heart disease drug plus a Wee inhibitor
PerkinElmer to rebrand as life-science-focused supplier, sell off other businesses in $2.45B deal
Merck's Keytruda, on a losing streak, fails in once FDA-rejected liver cancer use and prostate cancer—again
Bristol Myers' Opdivo-Yervoy combo joins Roche on the postsurgery kidney cancer flop list
Axcella misses primary endpoint in long COVID trial but plots path to market based on fatigue scores
Bose abandons hearing aid plans, hands off direct-to-consumer tech to Lexie Hearing
We're looking for 2022's Fiercest Women in Life Sciences

The Top Line is produced by senior multimedia producer Teresa Carey with editor-in-chief Tracy Staton, managing editor Querida Anderson and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.

It's earnings season—a time when publicly traded pharmas and biotechs tell their investors how they've performed over the previous quarter. But aside from drug sales figures, it’s a great opportunity to get a sense of how these companies' pipelines have changed. We'll dig into that, and even the stuff that companies are less keen to talk about. 
Regeneron once boasted one of the top COVID-19 therapeutics in its antibody cocktail REGEN-COV. Now, the company is terminating four studies for the med across a range of patients and clinical stages. The move follows the FDA’s decision to pull the medication from the market in January, citing uncertain efficacy against the surging omicron variant. And Regeneron’s antibody combo isn’t alone. We'll discuss how early pandemic therapeutics have fallen by the wayside.
To learn more about the topics in this episode: 
<ul>
<li><a href="https://www.fiercebiotech.com/biotech/astrazeneca-axes-moderna-partnered-phase-2-heart-disease-drug-amid-other-wee-pipeline">AstraZeneca axes Moderna-partnered, phase 2 heart disease drug plus a Wee inhibitor</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/bms-ambrx-collab-kaput-after-fa-relaxin-med-canned">BMS-Ambrx collab runs out of steam after FA relaxin med canned</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/takeda-cuts-ties-cancer-drug-landed-120m-turnstone-deal-part-pipeline-clear-out">Takeda cuts ties to cancer drug landed in $120M Turnstone deal</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/nash-curse-strikes-again-pfizer-dumps-early-stage-asset-liver-condition">The NASH curse strikes again. Pfizer dumps early-stage asset for liver condition</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/astrazeneca-axes-moderna-partnered-phase-2-heart-disease-drug-amid-other-wee-pipeline">AstraZeneca axes Moderna-partnered, phase 2 heart disease drug plus a Wee inhibitor</a></li>
<li><a href="https://www.fiercebiotech.com/medtech/perkinelmer-rebrand-life-science-focused-supplier-sell-other-businesses-245b-deal">PerkinElmer to rebrand as life-science-focused supplier, sell off other businesses in $2.45B deal</a></li>
<li><a href="https://www.fiercepharma.com/pharma/mercks-keytruda-losing-streak-fails-once-fda-rejected-liver-cancer-use-and-prostate-cancer">Merck's Keytruda, on a losing streak, fails in once FDA-rejected liver cancer use and prostate cancer—again</a></li>
<li><a href="https://www.fiercepharma.com/pharma/bristol-myers-opdivo-yervoy-combo-joins-roche-postsurgery-kidney-cancer-flop-list">Bristol Myers' Opdivo-Yervoy combo joins Roche on the postsurgery kidney cancer flop list</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/axcella-misses-primary-endpoint-long-covid-trial-plots-path-market-based-fatigue-scores">Axcella misses primary endpoint in long COVID trial but plots path to market based on fatigue scores</a></li>
<li><a href="https://www.fiercebiotech.com/medtech/bose-abandons-hearing-aid-plans-hands-direct-consumer-tech-lexie-hearing">Bose abandons hearing aid plans, hands off direct-to-consumer tech to Lexie Hearing</a></li>
<li><a href="https://www.fiercepharma.com/pharma/were-looking-2022s-fiercest-women-life-sciences">We're looking for 2022's Fiercest Women in Life Sciences</a></li>
</ul>
The Top Line is produced by senior multimedia producer Teresa Carey with editor-in-chief Tracy Staton, managing editor Querida Anderson and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning. 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.&nbsp;

The Top Line

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We’ll analyze the week’s biggest business news—from mergers and marketing to drug R&D and device development. Available every Friday morning.

 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We&rsquo;ll analyze the week&rsquo;s biggest business news&mdash;from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.
&nbsp;

Advertisement